GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm's investors include Alzheimer's Drug Discovery Foundation, MassChallenge, FONGIT Innovation Fund, Gliaven.
GliaPharm is headquartered in Geneva, Switzerland.
GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GliaPharm — Funding & Investors." VCBacked, September 17, 2024, https://www.vcbacked.co/company/gliapharm. Accessed October 5, 2026.
VCBacked. (2024). GliaPharm — Funding & Investors. Retrieved October 5, 2026, from https://www.vcbacked.co/company/gliapharm
{{cite web |title=GliaPharm — Funding & Investors |url=https://www.vcbacked.co/company/gliapharm |website=VCBacked |access-date=October 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated